01:04:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-10-23 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Ordinarie utdelning INIFY 0.00 NOK
2024-05-14 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-02-29 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-19 Ordinarie utdelning INIFY 0.00 NOK
2023-05-16 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-30 Extra Bolagsstämma 2022
2022-08-17 Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Inify Laboratories tillhandahåller cancerdiagnostik genom laboratorietjänster inom patologi. Bolaget använder ett digitalt, standardiserat arbetsflöde för svarstider och kvalitetssäkring, initialt inom prostata diagnostik. Kunderna består främst utav laboratorier och sjukhus. Inify Laboratories grundades år 2022 och har sitt huvudkontor i Stockholm, Sverige.
2023-02-22 08:00:15
STOCKHOLM - February 22, 2023 - Inify Laboratories, a company providing fully
digitalized laboratory services within prostate cancer diagnostics, has
completed its new laboratory - including staffing up with skilled professionals
- in less than a year.

"The laboratory has been finished in record time. We now have an ultramodern AI
-based laboratory, and a dedicated team with a broad spectrum of expertise
within digital pathology," says CEO Fredrik Palm at Inify Laboratories.

"Reached all milestones"

Total costs so far are in line with our expectations, due to good project
planning and successful teamwork within the company's interdisciplinary teams,
as well as close collaboration with external suppliers.

"The fourth quarter sees us reaching practically all the milestones required to
be able to start the new year with tests and validation of our complete system
before we launch our diagnostic service for prostate cancer. The launch is
expected to take place in the first half of 2023," says Palm.

"Setting a new world standard"

In early October, the company carried out successful tests of its unique IT
system, where every part of the process is standardized with full traceability.
The feedback from future customers - urology clinics and pathologists, with whom
Inify has had a close dialogue - has been highly positive.

"The response exceeded our already high expectations, and we close the year with
strong confidence that our first patients will be diagnosed according to
schedule," says Palm. "We continue at full speed towards our goal - setting a
new world standard in pathological cancer diagnostics, for the benefit of
doctors and patients."

For further information, please contact CEO Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com.

###

About Inify Laboratories

Inify Laboratories is currently building and establishing an ultramodern
laboratory that will provide cancer diagnostics within histopathology. Designed
from scratch, it uses a fully digital, standardized and AI-supported workflow to
optimize quality and shorten response times, initially within prostate cancer.
The first laboratory, located at Campus Solna Sweden, is estimated to start
offering services to both public and private healthcare providers before summer
2023.

The company originates from ContextVision, with nearly 40 years of experience
within digital imaging for medical applications and became independent through a
spin-off in February 2022. The company, based in Sweden, is listed on Euronext
Growth Oslo under the ticker INIFY.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.